NCT01335256View on ClinicalTrials.gov

Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Neoplasms
Interventions
DRUG

BAY1000394

BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.

Trial Locations (3)

27599

Chapel Hill

63110

St Louis

85258

Scottsdale

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01335256 - Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies | Biotech Hunter | Biotech Hunter